Advertisement
UK markets closed
  • FTSE 100

    7,706.28
    +21.79 (+0.28%)
     
  • FTSE 250

    19,179.56
    -83.94 (-0.44%)
     
  • AIM

    747.77
    -2.19 (-0.29%)
     
  • GBP/EUR

    1.1707
    +0.0015 (+0.13%)
     
  • GBP/USD

    1.2673
    +0.0015 (+0.12%)
     
  • Bitcoin GBP

    40,689.99
    +367.26 (+0.91%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,088.80
    +1.77 (+0.03%)
     
  • DOW

    39,131.53
    +62.42 (+0.16%)
     
  • CRUDE OIL

    76.57
    -2.04 (-2.60%)
     
  • GOLD FUTURES

    2,045.80
    +15.10 (+0.74%)
     
  • NIKKEI 225

    39,098.68
    +836.48 (+2.19%)
     
  • HANG SENG

    16,725.86
    -17.09 (-0.10%)
     
  • DAX

    17,419.33
    +48.88 (+0.28%)
     
  • CAC 40

    7,966.68
    +55.08 (+0.70%)
     

Some Patients Got Early Alzheimer’s From Contaminated HGH Treatment: Report

Clement Mahoudeau/Getty Images
Clement Mahoudeau/Getty Images

A new report published in the journal Nature Medicine found that some patients who received human growth hormone from the pituitary glands of cadaver donors from 1959 to 1985 developed early cases of Alzheimer’s, possibly from contaminated samples that featured a protein associated with the disease. A handful of patients in the study displayed symptoms of early onset Alzheimer’s, with the youngest at 38 years old, and others were found to have the associated protein in their brains when they died. Researchers concluded that it is possible to develop Alzheimer’s from the transfer of a contaminated hormone, but they cautioned against overextending the scope of the results. “We’re not suggesting for a moment you can catch Alzheimer’s disease. This is not transmissible in the sense of a viral or bacterial infection,” one of the co-authors of the study told the Guardian. The procedure that caused the patients in the study to degenerate has been discontinued for decades.

Read it at The Guardian

Read more at The Daily Beast.